Literature DB >> 10190536

Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.

M Kayikçioğlu1, F Ozerkan, I Soydan.   

Abstract

This randomized prospective clinical study evaluated the lipid-lowering effects and safety of a new combination regimen in patients with mixed hyperlipidemia. The data show that alternate-day simvastatin and fenofibrate therapy was as effective as the standard daily combination of the same drugs at the same doses, and it was safer, less expensive, and more tolerable.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10190536     DOI： 10.1016/s0002-9149(99)00030-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  7 in total

1.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

Authors:  Warner M Mampuya; David Frid; Michael Rocco; Julie Huang; Danielle M Brennan; Stanley L Hazen; Leslie Cho
Journal:  Am Heart J       Date:  2013-08-05       Impact factor: 4.749

2.  Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.

Authors:  Roberto Ferrari; Carlos Aguiar; Eduardo Alegria; Riccardo C Bonadonna; Francesco Cosentino; Moses Elisaf; Michel Farnier; Jean Ferrières; Pasquale Perrone Filardi; Nicolae Hancu; Meral Kayikcioglu; Alberto Mello E Silva; Jesus Millan; Željko Reiner; Lale Tokgozoglu; Paul Valensi; Margus Viigimaa; Michal Vrablik; Alberto Zambon; José Luis Zamorano; Alberico L Catapano
Journal:  Eur Heart J Suppl       Date:  2016-04-12       Impact factor: 1.803

Review 3.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 4.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

5.  Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.

Authors:  C Stefanutti; A Bucci; S Di Giacomo; N Fraone; A Pace; M Mareri; A Musca; A Mammarella
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  Combination drug therapy for combined hyperlipidemia.

Authors:  J R Guyton
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 3.955

Review 7.  Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Authors:  Nicola Tarantino; Francesco Santoro; Luisa De Gennaro; Michele Correale; Francesca Guastafierro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Vasc Health Risk Manag       Date:  2017-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.